At a glance
ClinicalIndex Comparison RecordN/ACompleted· 9 enrolled
Drug / intervention
Filgrastimdrug
Likely dose
Filgrastim 10 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
In Brief
A clinical study evaluating Filgrastim for Malignant Melanoma and Head and Neck Cancer. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more individualized treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma, Head and Neck Cancer
CountriesUnited States
CollaboratorsKarsh Family Research Fund
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMay 2015
Primary CompletionJul 2018
Study CompletionMar 2025
TodayJul 2026
First PostedJan 6, 2015
Enrollment StartMay 13, 2015
Primary CompletionJul 6, 2018
Study CompletionMar 6, 2025
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.5 years ago
Interventions
Filgrastimdrug
Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule